Lixte Biotechnology Holdings Inc (LIXT)

Currency in USD
5.880
-0.030(-0.51%)
Closed·
5.8800.000(0.00%)
·
Unusual trading volume
LIXT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.3006.050
52 wk Range
0.6406.260
Key Statistics
Prev. Close
5.91
Open
5.93
Day's Range
5.3-6.05
52 wk Range
0.64-6.26
Volume
140.91K
Average Volume (3m)
53.08K
1-Year Change
345.4545%
Book Value / Share
0.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LIXT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.18 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LIXT Income Statement

Compare LIXT to Peers and Sector

Metrics to compare
LIXT
Peers
Sector
Relationship
P/E Ratio
−9.3x−2.7x−0.5x
PEG Ratio
−0.33−0.070.00
Price/Book
8.6x2.5x2.6x
Price / LTM Sales
-6.7x3.1x
Upside (Analyst Target)
-113.5%53.0%
Fair Value Upside
Unlock0.4%6.3%Unlock

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.67M40.23%27.62M
Other Institutional Investors
-2.97M-25.56%-17.55M
Public Companies & Retail Investors
9.91M85.33%58.59M
Total
11.62M100.00%68.66M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Royal London Equity Funds ICVC - Royal London Emerging Markets ESG Leaders Equity Tracker Fund18.25%2,120,00012,466
BlackRock Collective Investment Funds - iShares Emerging Markets Equity Index Fund8.18%950,0405,586

People Also Watch

0.817
PHGE
+10.56%
0.08
WGRX
-18.69%
2.890
HCWB
+12.02%
3.160
NCEL
-0.63%
0.44
TDIC
-21.62%

FAQ

What Is the Lixte Bio (LIXT) Stock Price Today?

The Lixte Bio stock price today is 5.880 USD.

What Stock Exchange Does Lixte Bio Trade On?

Lixte Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lixte Bio?

The stock symbol for Lixte Bio is "LIXT."

What Is the Lixte Bio Market Cap?

As of today, Lixte Bio market cap is 68.310M USD.

What Is Lixte Bio's Earnings Per Share (TTM)?

The Lixte Bio EPS (TTM) is -1.054.

From a Technical Analysis Perspective, Is LIXT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Lixte Bio Stock Split?

Lixte Bio has split 2 times.

How Many Employees Does Lixte Bio Have?

Lixte Bio has 3 employees.

What is the current trading status of Lixte Bio (LIXT)?

As of May 23, 2026, Lixte Bio (LIXT) is trading at a price of 5.880 USD, with a previous close of 5.910 USD. The stock has fluctuated within a day range of 5.300 USD to 6.050 USD, while its 52-week range spans from 0.640 USD to 6.260 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.